Stock CVKD CADRENAL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Cadrenal Therapeutics, Inc.

Equities

CVKD

US1276361086

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
0.46 USD -5.23% Intraday chart for Cadrenal Therapeutics, Inc. -6.22% -37.83%
May. 09 Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 09 Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts CI

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer
CI
Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors
CI
Cadrenal Therapeutics, Inc. Announces Board Appointments
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CVKD Stock
  4. News Cadrenal Therapeutics, Inc.
  5. Insiders
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW